Halozyme Therapeutics
HALO
91.35
-1.69
-1.82%
Halozyme Therapeutics
US · HALO
#1276 by market cap
Listed 1970
91.35
-1.69
-1.82%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 4 in the most recent period (2026/Q4).
- Total institutional ownership fell 0.2 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 113.97% -0.20pp
- Institutions
- 912 -4
- As of
- 2026/Q4 vs. prior period
Holder types
Mutual Fund86.27%
Hedge Fund11.64%
Public Company7.63%
Private Company3.56%
Government Pension Fund2.46%
Sovereign Wealth Fund1.30%
Individual/Insider1.05%
Family Office/Trust0.63%
Insurance Company0.33%
Top holders as of 2026-09-30
BlackRock
11.99% · 13.67M sh
Vanguard Capital Management, LLC
5.12% · 5.84M sh
State Street Global Advisors
4.44% · 5.06M sh
Vanguard Portfolio Management, LLC
4.37% · 4.99M sh
Two Sigma Investments, LP
3.09% · 3.52M sh
D. E. Shaw & Co., L.P.
2.96% · 3.37M sh
Invesco Ltd.
2.58% · 2.94M sh
William Blair Investment Management, LLC
2.28% · 2.59M sh
Boston Partners Global Investors, Inc.
2.42% · 2.76M sh
Geode Capital Management, LLC
2.12% · 2.41M sh
Snyder Capital Management, L.P.
2.11% · 2.40M sh
Morgan Stanley
1.98% · 2.24M sh
Congress Asset Management Company, LLP
2.00% · 2.28M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 26 buys · 24 sells
| Name | Role | Stake |
|---|---|---|
| Helen Torley | Chief Executive Officer | 0.67% |
| Michael LaBarre | Former Chief Technology Officer | 0.15% |
| Mark Snyder | Executive VP, General Counsel, Chief Compliance Officer & Corporate Secretary | 0.04% |
| Matthew Posard | Independent Director | 0.04% |
| Nicole LaBrosse | Former Chief Financial Officer | 0.03% |
| Bernadette Connaughton | Independent Director | 0.03% |
| Jeffrey Henderson | Independent Chairperson | 0.03% |
| Akiko Moni Miyashita | Former Independent Director | 0.02% |
| Barbara Duncan | Independent Director | 0.01% |
| Mahesh Krishnan | Independent Director | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-07 | Helen Torley | Chief Executive Officer | Derivative Exercise and Sale | -60,000 | $18.41–113.69 |
| 2026-09-30 | James Daly | Director | Other Acquisition | +1,169 | -- |
| 2026-09-30 | James Daly | Director | Other Derivative Acquisition | +1,775 | $106.94 |
| 2026-09-30 | Matthew Posard | Independent Director | Automatic Disposition | -5,230 | $107.17–110.04 |
| 2026-09-15 | Matthew Posard | Independent Director | Automatic Disposition | -18,996 | $106.13–108.99 |
| 2026-09-10 | Helen Torley | Chief Executive Officer | Derivative Exercise and Sale | -60,000 | $18.41–108.67 |
| 2026-08-31 | Dannielle Appelhans | Director | Other Acquisition | +1,161 | -- |
| 2026-08-31 | Dannielle Appelhans | Director | Other Derivative Acquisition | +1,778 | $107.72 |
| 2026-08-18 | Helen Torley | Chief Executive Officer | Derivative Exercise and Sale | -60,000 | $18.41–107.77 |
| 2026-08-09 | Bernadette Connaughton | Independent Director | Automatic Disposition | -1,626 | $102.80 |
| 2026-07-07 | Helen Torley | Chief Executive Officer | Derivative Exercise and Sale | -1,923 | $12.07–80.19 |
| 2026-06-30 | David Ramsay | President of Drug Delivery | Other Derivative Acquisition | +16,232 | -- |
| 2026-06-30 | David Ramsay | President of Drug Delivery | Other Derivative Acquisition | +39,823 | $77.01 |
| 2026-06-30 | Bernadette Connaughton | Independent Director | Automatic Disposition | -1,625 | $76.40–77.21 |
| 2026-06-30 | Darren Snellgrove | Senior Vice President | Other Derivative Acquisition | +41,554 | -- |
| 2026-06-30 | Darren Snellgrove | Senior Vice President | Other Derivative Acquisition | +127,432 | $77.01 |
| 2026-06-29 | David Ramsay | President of Drug Delivery | Derivative Exercise and Sale | -5,408 | $78.27 |
| 2026-06-29 | David Ramsay | President of Drug Delivery | Derivative Exercise and Retained | +4,592 | -- |
| 2026-06-28 | Mahesh Krishnan | Independent Director | Derivative Exercise and Sale | -7,304 | $38.46–75.00 |
| 2026-06-11 | Mark Snyder | Executive VP, General Counsel, Chief Compliance Officer & Corporate Secretary | Derivative Exercise and Sale | -2,715 | $69.50 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:02:40 · For reference only, not investment advice and not tailored to your situation.
Halozyme Therapeutics discussion 0 comments